Alnylam Pharmaceuticals Inc’s recently made public that its Chief Executive Officer Greenstreet Yvonne unloaded Company’s shares for reported $9.63 million on May 30 ’25. In the deal valued at $304.39 per share,31,640 shares were sold. As a result of this transaction, Greenstreet Yvonne now holds 48,948 shares worth roughly $15.69 million.
Then, Greenstreet Yvonne sold 19,297 shares, generating $5,904,882 in total proceeds. Upon selling the shares at $306.00, the Chief Executive Officer now owns 48,948 shares.
Before that, Greenstreet Yvonne bought 19,297 shares. Alnylam Pharmaceuticals Inc shares valued at $5,848,824 were divested by the Officer at a price of $303.10 per share.
Truist initiated its Alnylam Pharmaceuticals Inc [ALNY] rating to a Buy in a research note published on July 21, 2025; the price target was $385. A number of analysts have revised their coverage, including Redburn Atlantic’s analysts, who began to cover the stock in late March with a ‘”a Buy”‘ rating. JP Morgan also remained covering ALNY and has increased its forecast on March 24, 2025 with a “an Overweight” recommendation from previously “Neutral” rating. Wolfe Research revised its rating on November 12, 2024. It rated ALNY as “an Underperform” which previously was an “a Peer perform”.
How much short interest is there in Alnylam Pharmaceuticals Inc?
A steep rise in short interest was recorded in Alnylam Pharmaceuticals Inc stocks on 2025-06-13, dropping by -0.31 million shares to a total of 3.38 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 3.68 million shares. There was a decline of -9.06%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 16, 2024 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating .
